Identificador persistente para citar o vincular este elemento: http://hdl.handle.net/10553/129865
Campo DC Valoridioma
dc.contributor.authorKassab, Baraa Nakdalien_US
dc.contributor.authorDe Pablos Rodríguez, Pedroen_US
dc.contributor.authorGómez Ferrer, Álvaroen_US
dc.contributor.authorCoy García, Antonioen_US
dc.contributor.authorCalatrava Fons, Anaen_US
dc.contributor.authorAragón, Fuensantaen_US
dc.contributor.authorRamón-Borja, Juan Casanovaen_US
dc.contributor.authorRamírez-Backhaus, Miguelen_US
dc.date.accessioned2024-04-15T11:52:21Z-
dc.date.available2024-04-15T11:52:21Z-
dc.date.issued2024en_US
dc.identifier.issn0004-0614en_US
dc.identifier.otherScopus-
dc.identifier.urihttp://hdl.handle.net/10553/129865-
dc.description.abstractBackground: Evidence regarding the relationship between the laterality of lymph node invasion (LNI) and the prostatic lobe affected is limited. Our aim was to review our records of patients with exclusively unilateral localised prostate cancer (PCa) with metastatic LN involvement. Methods: Between 2006 and 2023, after radical prostatectomy and extended pelvic lymphadenectomy at our centre, thirty patients with intermediate-high risk unilateral PCa and pN1 disease were identified. To perform a retrospective study, data were obtained from a prospective collected database approved by the ethical committee at the Valencian Oncology Institute Foundation. Descriptive and comparative statistical analysis was made using software R. The Fisher’s Exact test was employed to analyse the categorical variables. In terms of continuous variables, both tumour volume and number of nodes retrieved exhibited normality; Hence Student’s T-test was employed. Mann-Whitney U test was utilized for the number of positive nodes. Results: The median age and prostate specific antigen (PSA) at diagnosis were 66 years old (interquartile range (IQR): 63.3–70.9) and 14.6 ng/mL (IQR: 7.4–21.5), respectively. Median follow-up time was 67 months (IQR: 35.9–92.9). Nineteen patients (63%) had a Gleason score of 7, and the rest had a Gleason score of 8–10. Most patients (73%) had locally advanced disease. Baseline characteristics were comparable between groups (p-value > 0.05). Twenty-two patients (73%) had concordance between the laterality of the PCa lesion and the LNI. All the patients with right prostatic cancer had exclusive ipsilateral LNI. Conclusions: In our experience, the majority of patients with unilateral PCa had exclusively ipsilateral LNI. However, sparing contralateral LN dissection in unilateral PCa should not be an option. To date, extended pelvic LN dissection remains the gold standard for N-staging and cannot be replaced yet by unilateral pelvic LN dissection until high quality evidence supports this scenario.en_US
dc.languagespaen_US
dc.relation.ispartofArchivos españoles de urologíaen_US
dc.sourceArchivos Espanoles de Urologia [ISSN 0004-0614], v. 77 (2), p. 129-134, (Marzo 2024).en_US
dc.subject320101 Oncologíaen_US
dc.subject.otherLymph Node Dissectionen_US
dc.subject.otherLymph Node Invasionen_US
dc.subject.otherProstate Canceren_US
dc.subject.otherProstatic Laterality Lesionen_US
dc.titleIs Unilateral Lymphadenectomy an Option in Selected Patients with Prostate Cancer?en_US
dc.typeinfo:eu-repo/semantics/Articleen_US
dc.typeArticleen_US
dc.identifier.doi10.56434/j.arch.esp.urol.20247702.17en_US
dc.identifier.scopus85189350951-
dc.contributor.orcidNO DATA-
dc.contributor.orcidNO DATA-
dc.contributor.orcidNO DATA-
dc.contributor.orcidNO DATA-
dc.contributor.orcidNO DATA-
dc.contributor.orcidNO DATA-
dc.contributor.orcidNO DATA-
dc.contributor.orcidNO DATA-
dc.contributor.authorscopusid57450670000-
dc.contributor.authorscopusid57222092060-
dc.contributor.authorscopusid7101847888-
dc.contributor.authorscopusid58730880500-
dc.contributor.authorscopusid55626738500-
dc.contributor.authorscopusid57215089562-
dc.contributor.authorscopusid37006495800-
dc.contributor.authorscopusid14024715000-
dc.identifier.eissn1576-8260-
dc.description.lastpage134en_US
dc.identifier.issue2-
dc.description.firstpage129en_US
dc.relation.volume77en_US
dc.investigacionCiencias de la Saluden_US
dc.type2Artículoen_US
dc.utils.revisionen_US
dc.date.coverdateMarzo 2024en_US
dc.identifier.ulpgcen_US
dc.contributor.buulpgcBU-MEDen_US
dc.description.sjr0,22
dc.description.jcr0,5
dc.description.sjrqQ3
dc.description.jcrqQ4
dc.description.scieSCIE
dc.description.miaricds11,0
item.grantfulltextnone-
item.fulltextSin texto completo-
crisitem.author.fullNameDe Pablos Rodríguez, Pedro-
Colección:Artículos
Vista resumida

Visitas

61
actualizado el 31-ago-2024

Google ScholarTM

Verifica

Altmetric


Comparte



Exporta metadatos



Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.